NO20075821L - Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner - Google Patents

Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner

Info

Publication number
NO20075821L
NO20075821L NO20075821A NO20075821A NO20075821L NO 20075821 L NO20075821 L NO 20075821L NO 20075821 A NO20075821 A NO 20075821A NO 20075821 A NO20075821 A NO 20075821A NO 20075821 L NO20075821 L NO 20075821L
Authority
NO
Norway
Prior art keywords
women
testosterone
increasing testosterone
steroid concentrations
related steroid
Prior art date
Application number
NO20075821A
Other languages
English (en)
Inventor
Robert E Dudley
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of NO20075821L publication Critical patent/NO20075821L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter, sett, kombinasjoner og sammensetninger for å behandle, forebygge eller redusere risikoen for å utvikle en testosteronsviktlidelse eller symptomene som er assosiert med eller beslektet med en testosteronsviktlidelse i en pasient som har behov for dette.Den foreliggende oppfinnelsen angår også en fremgangsmåte for å administrere et steroid i testosteronsynteseveien til en pasient som har behov for dette.
NO20075821A 2005-04-13 2007-11-13 Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner NO20075821L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67075305P 2005-04-13 2005-04-13
PCT/US2006/013550 WO2006113242A2 (en) 2005-04-13 2006-04-11 Method of increasing testosterone and related steroid concentrations in women

Publications (1)

Publication Number Publication Date
NO20075821L true NO20075821L (no) 2008-01-07

Family

ID=37115670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075821A NO20075821L (no) 2005-04-13 2007-11-13 Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner

Country Status (7)

Country Link
US (1) US20070154533A1 (no)
EP (1) EP1868590A4 (no)
JP (1) JP2008536851A (no)
KR (1) KR20080016552A (no)
CA (1) CA2604431A1 (no)
NO (1) NO20075821L (no)
WO (1) WO2006113242A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
EP1750766B1 (en) * 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2011496A1 (en) * 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
CA2704117C (en) * 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
EP2682111A1 (en) 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20110202362A1 (en) * 2010-02-17 2011-08-18 Western Holdings, Llc Weight loss method and system for performing and monitoring the same
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
CN103687587A (zh) * 2011-05-13 2014-03-26 特利默生物医药有限公司 鼻内较低剂量强度睾酮凝胶制剂及其用于治疗性快感缺失病或性欲减退疾患的应用
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2907284T3 (es) 2013-03-15 2022-04-22 Marius Pharmaceuticals Llc Formulaciones de emulsión
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP6838146B2 (ja) * 2016-10-06 2021-03-03 ディーワイ ナチュラル カンパニー リミテッド ピニトール、ｄ−カイロ−イノシトール、又はこれらの類似化合物を有効成分として含む、女性の更年期症状の改善、予防、又は治療用の組成物
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
JPWO2023048174A1 (no) * 2021-09-22 2023-03-30

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
AU2001285367B2 (en) * 2000-08-30 2006-05-18 Besins Healthcare Luxembourg Sarl Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer

Also Published As

Publication number Publication date
EP1868590A4 (en) 2012-08-29
KR20080016552A (ko) 2008-02-21
WO2006113242A3 (en) 2009-05-07
US20070154533A1 (en) 2007-07-05
CA2604431A1 (en) 2006-10-26
EP1868590A2 (en) 2007-12-26
JP2008536851A (ja) 2008-09-11
WO2006113242A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20083877L (no) Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
NO20083303L (no) Fremgangsmater, sammensetinger og sett for behandling av muskel-skjelettsykdommer og symptomer assosiert dermed
NO20092637L (no) Fremgangsmater for behandling
NO20090156L (no) Humanisert antistoff
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
MX2007012353A (es) Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
NO20075304L (no) Metode for avtagende forkalkning
DK1836312T3 (da) Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration
TW200714277A (en) Methods and compositions for altering cell fuction
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application